RxDoctor Payments Data

George Gadea, DO

Internal Medicine · Tampa, FLNPI 1902869654

Payments from drug & device makers

$357in general payments, 2019–2025

Across 20 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$103
  • Novo Nordisk$85
  • Abbott$43
  • AbbVie$34
  • Amgen$31
  • Lilly USA, LLC$24
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$33193%
  • Education$267%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences5$103
Novo Nordisk5$85
Abbott2$43
AbbVie2$34
Amgen2$31
Lilly USA, LLC2$24
AstraZeneca1$19
Pfizer1$17

How this compares

$357 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$85,433
Medicare patients
148
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$127,342
MounjaroTirzepatide74$79,166
JardianceEmpagliflozin32$47,662
TrulicityDulaglutide35$41,677
RybelsusSemaglutide35$40,950
JanuviaSitagliptin Phosphate32$26,945
EliquisApixaban20$26,769
FarxigaDapagliflozin Propanediol25$18,661
JanumetSitagliptin Phos/Metformin Hcl12$17,678
XareltoRivaroxaban22$17,228
VascepaIcosapent Ethyl27$17,180
Tresiba Flextouch U-200Insulin Degludec19$15,118
Tresiba Flextouch U-100Insulin Degludec20$14,421
Repatha SureclickEvolocumab19$13,785
TrintellixVortioxetine Hydrobromide13$11,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$85$168,291153 claims
Lilly USA, LLCMounjaro, Trulicity$24$120,843109 claims
PfizerEliquis$17$26,76920 claims
AstraZenecaFarxiga$19$18,66125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →